DFMO (2-(difluoromethyl)ornithine), an ODC inhibitor, extended tumor latency in TH-MYCN mice, and combination treatment of DFMO with another polyamine synthesis inhibitor, SAM486, protected 40% of the mice from developing neuroblastoma. The gene discussed is MYCN; the disease is neoplasm.